Clinical Trial

A Polypill for Acute Coronary Syndrome

Study acronym: PolyACS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The current study aims to investigate whether combining the standard medications prescribed after acute coronary syndrome (ACS)-aspirin, P2Y12 inhibitors, and statins-into a single polypill can improve outcomes following an ACS event. Although these therapies are effective, gaps in adherence and uptake significantly contribute to risk or adverse events in the post-ACS period. This study is designed as a pragmatic, multi-center, randomized trial to assess the feasibility and effectiveness of a polypill-based strategy for treatment of ACS.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2029-08-01 -> 2030-06-01 2026-07-11
minor Completion pushed: 2029-08-01 -> 2030-07-31 2026-07-11
Trial Details
NCT Number NCT07032389
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Acute Coronary Syndrome
Enrollment 1,000 participants
Start Date 2025-12-05
Primary Completion 2030-06-01 (estimated)
Study Completion 2030-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-10